First-line talazoparib plus enzalutamide versus placebo plus enzalutamide in men with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial - Fay, André; Fizazi, Karim; Matsubara, Nobuaki; Azad, Arun A; Saad, Fred; De Giorgi, Ugo; Joung, Jae Young; Fong, Peter C C; Jones, Robert J; Zschäbitz, Stefanie; Oldenburg, Jan; Shore, Neal D; et al. (The lancet. Oncology, 2025)
Online verfügbar: 31. März 2025